Drug DiscoveryTrần Tín
Validate your metabolic targets and assess mitochondrial liability with energy metabolism
Metabolic pathway dysregulation is observed in many different pathological states including cancer, cardiovascular, and neurodegenerative diseases as well as obesity and diabetes. This means if you’re not considering energy metabolism in your target identification and validation studies, you could be missing important targets. Once compounds are in hand, assessing their mitochondrial toxicity in cells can reduce risk of adverse events later in the development process. Agilent cell metabolism platforms analyze live cells in real time so you can be sure that your targets and compounds are worth pursuing.